Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial

OBJECTIVE: Previous reports of the RAPID-axSpA trial (NCT01087762) described the efficacy and safety of certolizumab pegol (CZP) over 24 weeks in patients with axial spondyloarthritis (SpA), including ankylosing spondylitis (AS) and nonradiographic axial SpA. We report efficacy and safety data up to...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Arthritis Rheumatol
Main Authors: Sieper, J, Landewé, R, Rudwaleit, M, van der Heijde, D, Dougados, M, Mease, P J, Braun, J, Deodhar, A, Kivitz, A, Walsh, J, Hoepken, B, Nurminen, T, Maksymowych, W P
Format: Artigo
Sprog:Inglês
Udgivet: BlackWell Publishing Ltd 2015
Fag:
Spondyloarthritis
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4365732/
https://ncbi.nlm.nih.gov/pubmed/25470228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.38973
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker